Stand Up To Cancer and Johnson & Johnson announced a collaboration aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, to treat a rare disease called AL amyloidosis.
Stand Up To Cancer announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including head and neck, pediatric, pancreatic, breast, rectal, and gastro-esophageal cancers, as well as research focused on how the microbiome communicates with the immune system.
